Aquinox Pharmaceuticals LEADERSHIP Study – AQX-1125-201

Oakville, Ontario – August 26, 2013 – CMX Research Inc. is pleased to announce that it has commenced the clinical phase of the LEADERSHIP Study, where AQX-1125, a potent SHIP1 activator sponsored by Aquinox Pharmaceuticals Inc., is being investigated for the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC). CMX Research Inc. randomized the first patient mid-July, 2013, which was consistent with timelines originally set at the trial’s outset. The trial is scheduled for completion in the second half of 2014.

For more information on the press release issued by Aquinox Pharmaceuticals please follow the below link: